Notable Wednesday Option Activity: GRAL, GOSS, FTAI

Gossamer Bio (GOSS) saw unusually large options activity with 41,590 contracts traded (~4.2M underlying shares), equal to roughly 88.3% of its one‑month average daily volume; the $7 March 20, 2026 call accounted for 22,747 contracts (~2.3M shares). FTAI Aviation (FTAI) registered 9,598 option contracts (~959,800 underlying shares), about 85.2% of its one‑month average daily volume, led by 1,687 contracts in the $270 Feb 20, 2026 call (~168,700 shares). The flows signal concentrated call buying and significant positioning in both small‑cap names that could influence short‑term price dynamics or liquidity for active traders and event‑driven funds.

Analysis

Market structure: The outsized option flow (GOSS ~2.3M underlying via $7 Mar-20-2026 calls; FTAI ~169k via $270 Feb-20-2026 calls) benefits directional buyers and short-dated market-makers who will delta-hedge by buying/selling stock, creating transient demand that can move price 10–30% intraday in thinly supplied names. Direct losers are passive sellers and short sellers caught in gamma squeezes; expect near-term skew and implied volatility (IV) to remain elevated until positions unwind. Cross-asset effects are likely limited to equities and equity-financing markets (repo/funding spreads) rather than bonds, FX or commodities unless flow becomes systemic.

Risk assessment: Tail risks include an idiosyncratic corporate event (M&A, FDA outcome for GOSS) or a concentrated options position being closed, producing violent IV collapse; model a 40–60% IV drop scenario that would wipe out long-call P&L. Immediate (days): potential gamma squeeze; short-term (weeks–months): IV reprice and information leakage; long-term (quarters): fundamentals reassert. Hidden dependencies: block trades, direction of “buy-to-open” vs “sell-to-open,” and counterparties’ hedging cadence—monitor open interest and clearing-house reports.

Trade implications: For GOSS, prefer defined-risk bullish exposure (buy 7–12 Mar-2026 call spreads) or small equity exposure (1–2% portfolio) with protective 10–12% stops; avoid naked long calls because IV is rich. For FTAI, fade extreme strike action with a 30–60 day calendar or sell premium (iron-condor/covered call) sized conservatively (0.5–1% portfolio) because $270 strikes look speculative. Use pair trades (long GOSS vs short IBB or XBI) to isolate idiosyncratic move and hedge sector risk.

Contrarian angles: The market will read heavy call volume as bullish, but flow-driven rallies often reverse once market-makers unwind; this is likely underpriced. Historical parallels (options-driven squeezes) show sharp spikes followed by 20–50% retracement within 2–6 weeks in non-fundamental moves. Unintended consequence: a buyer executing a long-dated synthetic or spread could compress IV on expiry—be ready to flip from long-vol to short-vol within 1–3 weeks if OI/IP metrics show flattening.

Key Decisions for Investors

• Establish a tactical 1–2% portfolio long in GOSS via a defined-risk call spread: buy Mar-20-2026 $7/$12 call spread (or nearest strikes) sized to limit max loss to ~1% of portfolio; trim half if GOSS rallies >25% within 5 trading days, stop-loss equity move of -12%.
• For FTAI, implement a short-duration premium sell: sell a Feb-20-2026 calendar/iron-condor around the $270 call (delta exposure capped) representing 0.5–1% portfolio risk; exit if IV rises >30% or stock moves >15% intraday.
• Construct a pair trade to isolate idiosyncratic risk: long GOSS (1% net) funded by short biotech ETF exposure (sell 0.75% notional XBI) to hedge sector beta; reassess after 30–60 days or upon any FDA/M&A filing.
• Monitor three triggers over next 30 days before adding size: (1) cumulative open interest in GOSS $7 calls >30k traded or put/call ratio <0.4, (2) any Form 4 insider transactions or 8-K within 72 hours, (3) IV change >25% — act to reduce or flip position if any trigger occurs.